LONDON

伦敦

,

，

Sept. 30, 2026

2026年9月30日

/PRNewswire/ --

/美通社/ --

Clarenta today announced that Leads To Development (L2D) has joined Clarenta Group following a majority investment, strengthening Clarenta's ability to support biotech and pharmaceutical sponsors from preclinical drug development strategy through first-in-human clinical trials and beyond.

Clarenta 今日宣布，在获得多数股权投资后，Leads To Development（L2D）已加入 Clarenta 集团，此举增强了 Clarenta 支持生物技术和制药赞助商的能力，服务范围涵盖从临床前药物开发策略到首次人体临床试验及后续阶段。

The partnership adds specialist non-clinical development, manufacturing, and regulatory strategy expertise at the critical early stages of drug development.

该合作伙伴关系在药物开发的关键早期阶段增添了专业的非临床开发、生产和监管战略专业知识。

Continue Reading

继续阅读

L2D joined Clarenta group

L2D 加入 Clarenta 集团

Based in France, L2D supports innovative biotech and pharmaceutical companies by defining development pathways, gathering and assessing preclinical evidence, initiating and trouble-shooting manufacturing, and creating regulatory strategies that help new therapies progress towards and through the clinic as efficiently as possible..

L2D 总部位于法国，通过定义开发路径、收集并评估临床前证据、启动及解决生产过程中的问题，以及制定监管策略，支持创新型生物技术和制药公司，助力新疗法尽可能高效地推进并完成临床试验。

Together with Clarenta's existing early development consulting expertise and Early Phase Unit, L2D's capabilities strengthen the connection between early scientific strategy and first-in-human clinical research.

结合Clarenta现有的早期开发咨询专业知识及其早期阶段部门，L2D的能力加强了早期科学策略与首次人体临床研究之间的联系。

L2D joins Clarenta Group shortly after the launch of its new brand identity, marking another significant step in the Group's strategy to build an integrated early development partner for biotech and pharmaceutical sponsors. They will continue to operate from their Paris HQ as a specialist team, supporting existing and new clients while being strengthened by the broader capabilities of Clarenta Group..

L2D 在其全新品牌形象发布后不久加入 Clarenta 集团，标志着集团在打造面向生物技术和制药赞助商的整合型早期开发合作伙伴战略方面又迈出重要一步。L2D 将继续作为专业团队在巴黎总部运营，依托 Clarenta 集团更强大的综合能力，为现有及新客户提供支持。

Leadership Commentary

领导力评论

'Welcoming L2D into Clarenta Group is an important step in building the company we want Clarenta to be,'

“欢迎L2D加入Clarenta集团，这是朝着我们希望Clarenta成为的公司迈出的重要一步。”

said

说

Dr. Chris Smyth

克里斯·史密斯博士

, CEO of Clarenta

，Clarenta 首席执行官

.

。

'Our focus is on helping clients navigate complexity from the earliest stages of development. L2D brings deep non-clinical, manufacturing and regulatory expertise that complements our existing strengths and helps sponsors connect the decisions made before the clinic with the realities of early clinical development.'.

“我们的重点是帮助客户在开发的最早阶段应对复杂性。L2D 带来深厚的非临床、生产和监管专业知识，这些知识补充了我们现有的优势，并帮助申办方将临床试验前的决策与早期临床开发的现实情况相结合。”

'This exciting partnership allows L2D to remain focused on the specialist non-clinical development expertise that defines us while benefitting from the huge level of clinical experience within the Clarenta Group,'

“这一令人振奋的合作伙伴关系使 L2D 能够继续专注于定义我们的专业非临床开发专长，同时受益于 Clarenta 集团丰富的临床经验。”

said

说

Jonathan Kearsey

乔纳森·基尔西

, Managing Director and Co-Founder of Leads To Development

Leads To Development 的董事总经理兼联合创始人

.

。

'Our clients trust us to solve complex scientific and regulatory questions in the early stages of development – working alongside Clarenta enables us to connect those preclinical decisions with clinical strategies that deliver optimal, derisked and successful programmes.'

“我们的客户信任我们在开发早期阶段解决复杂的科学和监管问题——与Clarenta合作使我们能够将这些临床前决策与能够提供最优、降低风险且成功的项目的临床策略联系起来。”

'L2D is a strong strategic fit with Clarenta and the direction in which we are building the Group,'

“L2D与Clarenta具有高度的战略契合性，也符合我们集团的发展方向。”

said

说

Christopher Backes

克里斯托弗·巴克斯

, Co-Founder of EdgeCap Partners, the majority investor in Clarenta

，EdgeCap Partners 联合创始人，Clarenta 的控股股东

.

。

'The partnership adds specialist expertise at the beginning of the development journey, where better decisions can create meaningful value for clients, while preserving the focus and expertise that have made L2D successful.'

“该合作关系在开发旅程的初期增添了专业专长，此时更优的决策能够为客户创造显著价值，同时保持使L2D取得成功的专注与专业能力。”

About Clarenta

关于 Clarenta

Clarenta, formerly Comac Medical Group, is a European clinical development partner helping biotech and pharmaceutical companies navigate complex clinical development with clarity, foresight and confidence. Clarenta connects early development strategy, regulatory expertise and clinical execution, from studies in its Phase I Unit to clinical delivery across Europe..

Clarenta（前身为Comac Medical Group）是一家欧洲临床开发合作伙伴，帮助生物科技和制药公司以清晰、前瞻性和信心应对复杂的临床开发。Clarenta将早期开发战略、监管专业知识和临床执行相结合，服务范围涵盖其I期单元的研究以及在整个欧洲的临床交付。

www.clarenta.com

www.clarenta.com

About Leads To Development

关于 Leads To Development

Based in Paris, France, Leads To Development (L2D) provides specialist non-clinical development and regulatory consultancy alongside hands-on operations support. For over 15 years', they have helped biotech and pharmaceutical companies excel in their early-stage drug development.

Leads To Development (L2D) 总部位于法国巴黎，提供专业化的非临床开发与监管咨询，并结合实际操作支持。十五年来，该公司一直助力生物技术和制药公司在早期药物开发领域取得卓越成就。

www.leadstodevelopment.com

www.leadstodevelopment.com

[email protected]

[email protected]

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示